Pollinex Quattro Birch: Ph III B301 started

Allergy Therapeutics began the double-blind, placebo-controlled, European Phase III B301 trial to evaluate 900, 2,400 and 6,000 standardized units/mL subcutaneous Pollinex Quattro Birch in about 562 p...